2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Insights from epidemiological, clinical and basic research are illuminating the interplay between metabolic disorders, cardiovascular disease (CVD) and kidney dysfunction, termed cardio‐renal‐metabolic (CRM) disease. Broadly defined, CRM disease involves multidirectional interactions between metabolic diseases such as type 2 diabetes (T2D), various types of CVD and chronic kidney disease (CKD). T2D confers increased risk for heart failure, which—although well known—has only recently come into focus for treatment, and may differ by ethnicity, whereas atherosclerotic heart disease is a well‐established complication of T2D. Many people with T2D also have CKD, with a higher risk in Asians than their Western counterparts. Furthermore, CVD increases the risk of CKD and vice versa, with heart failure, notably, present in approximately half of CKD patients. Molecular mechanisms involved in CRM disease include hyperglycaemia, insulin resistance, hyperactivity of the renin‐angiotensin‐aldosterone system, production of advanced glycation end‐products, oxidative stress, lipotoxicity, endoplasmic reticulum stress, calcium‐handling abnormalities, mitochondrial malfunction and deficient energy production, and chronic inflammation. Pathophysiological manifestations of these processes include diabetic cardiomyopathy, vascular endothelial dysfunction, cardiac and renal fibrosis, glomerular hyperfiltration, renal hypoperfusion and venous congestion, reduced exercise tolerance leading to metabolic dysfunction, and calcification of atherosclerotic plaque. Importantly, recognition of the interaction between CRM diseases would enable a more holistic approach to CRM care, rather than isolated treatment of individual conditions, which may improve patient outcomes. Finally, aspects of CRM diseases may differ between Western and East Asian countries such as Japan, a super‐ageing country, with potential differences in epidemiology, complications and prognosis that represent an important avenue for future research.

          Related collections

          Most cited references135

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

          Summary Background Health system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to impaired kidney function, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout. Methods The main data sources we used were published literature, vital registration systems, end-stage kidney disease registries, and household surveys. Estimates of CKD burden were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool, and included incidence, prevalence, years lived with disability, mortality, years of life lost, and disability-adjusted life-years (DALYs). A comparative risk assessment approach was used to estimate the proportion of cardiovascular diseases and gout burden attributable to impaired kidney function. Findings Globally, in 2017, 1·2 million (95% uncertainty interval [UI] 1·2 to 1·3) people died from CKD. The global all-age mortality rate from CKD increased 41·5% (95% UI 35·2 to 46·5) between 1990 and 2017, although there was no significant change in the age-standardised mortality rate (2·8%, −1·5 to 6·3). In 2017, 697·5 million (95% UI 649·2 to 752·0) cases of all-stage CKD were recorded, for a global prevalence of 9·1% (8·5 to 9·8). The global all-age prevalence of CKD increased 29·3% (95% UI 26·4 to 32·6) since 1990, whereas the age-standardised prevalence remained stable (1·2%, −1·1 to 3·5). CKD resulted in 35·8 million (95% UI 33·7 to 38·0) DALYs in 2017, with diabetic nephropathy accounting for almost a third of DALYs. Most of the burden of CKD was concentrated in the three lowest quintiles of Socio-demographic Index (SDI). In several regions, particularly Oceania, sub-Saharan Africa, and Latin America, the burden of CKD was much higher than expected for the level of development, whereas the disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, Australasia, and western Europe was lower than expected. 1·4 million (95% UI 1·2 to 1·6) cardiovascular disease-related deaths and 25·3 million (22·2 to 28·9) cardiovascular disease DALYs were attributable to impaired kidney function. Interpretation Kidney disease has a major effect on global health, both as a direct cause of global morbidity and mortality and as an important risk factor for cardiovascular disease. CKD is largely preventable and treatable and deserves greater attention in global health policy decision making, particularly in locations with low and middle SDI. Funding Bill & Melinda Gates Foundation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045

            To provide global, regional, and country-level estimates of diabetes prevalence and health expenditures for 2021 and projections for 2045.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Global aetiology and epidemiology of type 2 diabetes mellitus and its complications

              Globally, the number of people with diabetes mellitus has quadrupled in the past three decades, and diabetes mellitus is the ninth major cause of death. About 1 in 11 adults worldwide now have diabetes mellitus, 90% of whom have type 2 diabetes mellitus (T2DM). Asia is a major area of the rapidly emerging T2DM global epidemic, with China and India the top two epicentres. Although genetic predisposition partly determines individual susceptibility to T2DM, an unhealthy diet and a sedentary lifestyle are important drivers of the current global epidemic; early developmental factors (such as intrauterine exposures) also have a role in susceptibility to T2DM later in life. Many cases of T2DM could be prevented with lifestyle changes, including maintaining a healthy body weight, consuming a healthy diet, staying physically active, not smoking and drinking alcohol in moderation. Most patients with T2DM have at least one complication, and cardiovascular complications are the leading cause of morbidity and mortality in these patients. This Review provides an updated view of the global epidemiology of T2DM, as well as dietary, lifestyle and other risk factors for T2DM and its complications.
                Bookmark

                Author and article information

                Contributors
                t-kadowaki@toranomon.kkr.or.jp
                Journal
                Diabetes Obes Metab
                Diabetes Obes Metab
                10.1111/(ISSN)1463-1326
                DOM
                Diabetes, Obesity & Metabolism
                Blackwell Publishing Ltd (Oxford, UK )
                1462-8902
                1463-1326
                25 August 2022
                December 2022
                : 24
                : 12 ( doiID: 10.1111/dom.v24.12 )
                : 2283-2296
                Affiliations
                [ 1 ] Toranomon Hospital Tokyo Japan
                [ 2 ] Yasu City Hospital Shiga Japan
                [ 3 ] Department of Metabolism and Endocrinology Juntendo University Tokyo Japan
                [ 4 ] Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology Gifu University Graduate School of Medicine Gifu Japan
                [ 5 ] Yutaka Seino Distinguished Center for Diabetes Research Kansai Electric Power Medical Research Institute Kyoto Japan
                [ 6 ] Preemptive Food Research Center Gifu University Institute for Advanced Study Gifu Japan
                [ 7 ] Center for Healthcare Information Technology Tokai National Higher Education and Research System Nagoya Japan
                [ 8 ] Department of Cardiovascular Medicine Saga University Saga Japan
                [ 9 ] Department of Cardiology Nagoya University Nagoya Japan
                [ 10 ] Department of Nephrology, Rheumatology, Endocrinology and Metabolism Okayama University Okayama Japan
                Author notes
                [*] [* ] Correspondence

                Takashi Kadowaki, MD, President of Toranomon Hospital, 2‐2‐2 Toranomon, Minato‐ku, Tokyo 105‐8470, Japan.

                Email: t-kadowaki@ 123456toranomon.kkr.or.jp

                Author information
                https://orcid.org/0000-0002-4611-8149
                https://orcid.org/0000-0001-5961-1816
                https://orcid.org/0000-0002-5334-7687
                https://orcid.org/0000-0002-2534-0939
                https://orcid.org/0000-0003-1468-5170
                Article
                DOM14829
                10.1111/dom.14829
                9804928
                35929483
                ffa04650-fd63-4e85-8862-53c9dbfd955b
                © 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 18 July 2022
                : 27 April 2022
                : 01 August 2022
                Page count
                Figures: 2, Tables: 1, Pages: 14, Words: 11365
                Funding
                Funded by: Nippon Boehringer Ingelheim Co. Ltd. and Eli Lilly Japan K.K.
                Funded by: Eli Lilly Japan , doi 10.13039/100014422;
                Funded by: Boehringer Ingelheim , doi 10.13039/100001003;
                Categories
                Review Article
                Review Articles
                Custom metadata
                2.0
                December 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.3 mode:remove_FC converted:31.12.2022

                Endocrinology & Diabetes
                cardiovascular disease,diabetic nephropathy,heart failure,type 2 diabetes

                Comments

                Comment on this article